Immatics Appoints Arnd Christ as Chief Financial Officer
September 29 2020 - 7:00AM
Tuebingen, Germany and Houston, Texas,
September 29, 2020 – Immatics N.V. (NASDAQ: IMTX,
“Immatics”), a clinical-stage biopharmaceutical company active in
the discovery and development of T cell redirecting cancer
immunotherapies, announced today that Arnd Christ will join its
leadership team as Chief Financial Officer (CFO) as of October 1,
2020. Arnd Christ was previously the CFO of InflaRx, a
NASDAQ-listed biopharmaceutical company. Immatics’ current CFO,
Thomas Ulmer, is stepping down to pursue new opportunities.
Harpreet Singh, PhD, Chief Executive Officer at
Immatics, commented: “We welcome Arnd who brings extensive
experience and a track-record of effectively managing financial
operations within the public marketplace. His strategic leadership
will serve us well as we continue to meet our development
objectives for our T cell receptor-based therapeutics. I would also
like to sincerely thank Thomas Ulmer for all his contributions to
our organization to date, in particular for the transformation of
Immatics from a private to a public company. On behalf of the
entire Immatics team, I wish him the very best in his future
endeavors.”
Arnd Christ added: “Immatics’ clinical pipeline,
based on its unique target discovery and T cell receptor platforms,
has significant potential to transform the lives of cancer
patients. I am excited to become a part of this dynamic
organization, and to support its continued development going
forward.”
Arnd Christ brings nearly two decades of
experience serving as CFO of both private and public biotechnology
companies. Before joining InflaRx, he was CFO of several companies
including Medigene AG, Novimmune SA and Probiodrug AG. Over the
course of his career, Arnd Christ completed a broad range of
corporate transactions including an IPO, capital raises and
licensing deals. Prior to serving as a CFO, he held the position of
Financial Director in various corporations related to the former
Hoechst Group in Germany and the UK. Arnd Christ holds a master’s
degree in business administration from the University of Würzburg,
Germany.
Notes to Editors
About ImmaticsImmatics combines
the discovery of true targets for cancer immunotherapies with the
development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This
deep know-how is the foundation for our pipeline of Adoptive Cell
Therapies and TCR Bispecifics as well as our partnerships with
global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
For regular updates about Immatics, visit
www.immatics.com. You can also follow us on Twitter and
LinkedIn.
Forward-Looking
Statements:Certain statements in this press release may be
considered forward-looking statements. Forward-looking statements
generally relate to future events or Immatics’ future financial or
operating performance. For example, statements concerning the
timing of product candidates and Immatics’ focus on partnerships to
advance its strategy are forward-looking statements. In some cases,
you can identify forward-looking statements by terminology such as
“may”, “should”, “expect”, “intend”, “will”, “estimate”,
“anticipate”, “believe”, “predict”, “potential” or “continue”, or
the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks,
uncertainties, and other factors which could cause actual results
to differ materially from those expressed or implied by such
forward looking statements. These forward-looking statements are
based upon estimates and assumptions that, while considered
reasonable by Immatics and its management, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to, various factors beyond management's control including general
economic conditions and other risks, uncertainties and factors set
forth in filings with the Securities and Exchange Commission (SEC).
Nothing in this presentation should be regarded as a representation
by any person that the forward-looking statements set forth herein
will be achieved or that any of the contemplated results of such
forward-looking statements will be achieved. You should not place
undue reliance on forward-looking statements, which speak only as
of the date they are made. Immatics undertakes no duty to update
these forward-looking statements.
For more information, please
contact:
For media enquiries |
Investor
Relations Contact |
Gretchen Schweitzer or Jacob Verghese, PhD |
John
Graziano |
Trophic Communications |
Solebury
Trout |
Phone: +49 89 2388 7731 |
Phone: +1
646-378-2942 |
immatics@trophic.eu |
jgraziano@soleburytrout.com |
|
|
Immatics N.V. |
|
Anja Heuer |
Jordan
Silverstein |
Corporate Communications |
Head of
Strategy |
Phone: +49 89 540415-606 |
Phone: +1
281-810-7545 |
media@immatics.com |
InvestorRelations@immatics.com |
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Apr 2023 to Apr 2024